SPAIN—Cinfa, a leading pharmaceutical company with over 55 years of experience in the Spanish market, has unveiled its new state-of-the-art manufacturing plant in Spain, known as Neo.
This facility, representing a US $44 million investment, incorporates advanced Industry 4.0 technology, setting new standards in the pharmaceutical industry.
With a team of over 2,200 professionals, Cinfa has established a strong global presence, operating in more than 100 countries.
The company’s commitment to healthcare extends beyond borders, ensuring patients around the world have access to quality medications.
During the announcement, Enrique Ordieres, President of Cinfa Group, emphasized that the new Neo plant reflects the company’s ongoing dedication to meeting patient needs with high-quality treatments.
The Neo plant is based on the concept of ‘Industry 4.0,’ also known as the ‘smart factory.’
This means that all production systems are digitally integrated and automated, tailored to the specific requirements of each medication and its production stages.
By implementing a vertical production system, Cinfa has enhanced its manufacturing processes, increased capacity, and improved both quality and prevention standards.
In line with its commitment to sustainability, Cinfa designed the new plant with maximum energy efficiency in mind.
The plant’s environmental focus aligns with the company’s broader sustainability policy, emphasizing responsible use of natural resources and effective waste management.
Over the past four years, Cinfa has successfully reduced its carbon footprint intensity by 57%.
Enrique Ordieres went on to highlight that “sustainability and caring for our environment are priorities, and all business decisions incorporate environmental considerations.”
The Neo plant also features thermal energy recovery systems and an extensive photovoltaic installation.
The 1,900 m² solar array is an expansion of the solar park Cinfa launched in 2020, which has now been expanded to 15,000 m², equivalent to twelve Olympic swimming pools.
Cinfa is poised to double its annual production capacity with the new facility.
The plant will initially focus on producing 15 medications to treat widespread conditions like hypertension, which affects around 33% of adults in the Middle East and North Africa.
In addition to its manufacturing advancements, Cinfa has invested over US$474 million in research and development over the past decade.
The company has also made significant contributions to social initiatives, donating more than 2 million euros (US$2.1 million) in the last three years to support the Sustainable Development Goals (SDGs), particularly in improving healthcare access for vulnerable communities.
Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
